Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 5, 2013, Pages 529-550

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Glucose lowering therapy; Oral antidiabetic agent; Pharmacokinetics; Renal impairment; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN DERIVATIVE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MITIGLINIDE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; AREA UNDER THE CURVE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CREATININE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS;

EID: 84874125170     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.777428     Document Type: Review

References (164)

1. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and. stratification. Am J Kidney Dis 2002;39:S1-266
2. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154
3. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86
4. Detournay B, Simon D, Guillausseau PJ, et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 2012;38:102-12
5. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9
6. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
7. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53:S11-21
8. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl 4):73-85
9. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010;23:163-8 1
10. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-79 1
11. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43 1
12. Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011;34(Suppl 2):S330-4 1
13. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69 1
14. Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med 2009;121:52-60 1
15. Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012;60:747-69 1
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96 1
17. Scheen AJ. Medications in the kidney. Acta Clin Belg 2008;63:76-80 1
18. Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 2009;24:338-41 1
19. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36 2
20. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009;7:324-42 2
21. Rigalleau V, Beauvieux MC, Gonzalez C, et al. Estimation of renal function in patients with diabetes. Diabetes Metab 2011;37:359-66 2
22. McFarland MS, Markley BM, Zhang P, et al. Evaluation of modification of diet in renal disease study and Cockcroft-Gault equations for sitagliptin dosing. J Nephrol 2012;25:515-22 2
23. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87 2
24. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33:727-40 2
25. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point? Diabetologia 2005;48:2454-9 2
26. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit/ risk balance in "at risk" patients with type 2 diabetes. Diabetes Metab 2013; Submitted 2
27. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71 2
28. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98 2
29. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306 3
30. Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013;93:186-94 3
31. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93 3
32. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46 3
33. Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995;35:1094-102 3
34. Lalau JD, Vermersch A, Hary L, et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990;28:329-32 3
35. Frid A, Sterner GN, Londahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 2010;33:1291-3 3
36. Duong JK, Roberts DM, Furlong TJ, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012;14:963-5 3
37. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7 3
38. Lalau JD, Andrejak M, Moriniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989;27:285-8 3
39. Dichtwald S, Weinbroum AA, Sorkine P, et al. Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy. Diabet Med 2012;29:245-50 4
40. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503 4
41. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111-19 4
42. Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31 4
43. Philbrick AM, Ernst ME, McDanel DL, et al. Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? Am J Health Syst Pharm 2009;66:2017-23 4
44. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8 4
45. Vasisht KP, Chen SC, Peng Y, et al. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010;12:1079-83 4
46. Pongwecharak J, Tengmeesri N, Malanusorn N, et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 2009;31:481-6 4
47. Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005;28:922-4 4
48. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9 4
49. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380-3 5
50. Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010;15:412-18 5
51. del Pozo-Fernandez C, Pardo-Ruiz C, Sanchez-Botella C, et al. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. Nefrologia 2012;32:367-73 5
52. Rocha A, Almeida M, Santos J, et al. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol 2013;26:55-60 5
53. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012;11:597-614 5
54. Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonylurea-induced hypoglycemia. J Am Med Dir Assoc 2012;13:234-8 5
55. Holstein A, Hammer C, Hahn M, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010;9:675-81 5
56. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7 5
57. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012;81:698-706 5
58. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996;28:434-9 5
59. Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981;6:215-41 6
60. Ueda H, Sakurai T, Ota M, et al. Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease. Diabetes 1963;12:414-19 6
61. Petitpierre B, Perrin L, Rudhardt M, et al. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 1972;6:120-4 6
62. Rydberg T, Jonsson A, Roder M, et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30 6
63. Pearson JG, Antal EJ, Raehl CL, et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986;39:318-24 6
64. Jonsson A, Rydberg T, Sterner G, et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-35 6
65. Brier ME, Bays H, Sloan R, et al. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997;29:907-11 6
66. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41 6
67. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-5 6
68. Weir MA, Gomes T, Mamdani M, et al. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant 2011;26:1888-94 6
69. Aspinall SL, Zhao X, Good CB, et al. Intervention to decrease glyburide use in elderly patients with renal insufficiency. Am J Geriatr Pharmacother 2011;9:58-68 7
70. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-24 7
71. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73 7
72. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1983;21:98-107 7
73. Balant L, Zahnd G, Gorgia A, et al.Pharmacokinetics of glipizide in man: influence of renal insufficiencyDiabetologia 1973;331-8 7
74. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2012;published on line 2012/12/19; doi: 10.2337/dc12-1365 7
75. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013;published on line 2013/01/29; doi: 10.1053/j.ajkd.2012.11.043 7
76. Campbell DB, Gordon BH, Ings RMJ, et al. The effect of renal disease on the pharmacokinetics of gliclazide in diabetic patients. Br J Clin Pharmacol 1986;21:572-3 7
77. Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease-recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Medl Wkly 2012;142:w13629 7
78. Drouin P, Standl E. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004;6:414-21 7
79. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42 8
80. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 8
81. Malaisse WJ. Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 2006;7:331-7 8
82. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:249-72 8
83. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120 8
84. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-52 8
85. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91 8
86. Devineni D, Walter YH, Smith HT, et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003;43:163-70 8
87. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108 8
88. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000;67:7-15 8
89. Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-5 9
90. Nagai T, Imamura M, Iizuka K, et al. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003;59:191-4 9
91. Abe M, Okada K, Maruyama T, et al. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 2010;57:579-86 9
92. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-54 9
93. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59:521-49 9
94. Abe M, Kikuchi F, Kaizu K, et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007;68:287-94 9
95. Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-76 9
96. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006;154:613-21 9
97. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-33 9
98. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28 9
99. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741-53 10
100. Betteridge DJ. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011;28:759-71 10
101. Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009;20:1094-101 10
102. Brunelli SM, Thadhani R, Ikizler TA, et al. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009;75:961-8 10
103. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23:861-5 10
104. Fritsche L, Budde K, Glander P, et al. Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. Int J Clin Pharmacol Ther 2003;41:488-91 10
105. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74 10
106. Abe M, Kikuchi F, Okada K, et al. Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Ther Apher Dial 2009;13:238-9 10
107. Abe M, Okada K, Maruyama T, et al. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:1611-20 10
108. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008;19:182-7 10
109. Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012;98:175-86 11
110. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000;28:772-80 11
111. Chapelsky MC, Thompson-Culkin K, Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003;43:252-9 11
112. Thompson-Culkin K, Zussman B, Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002;30:391-9 11
113. Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 2008;33:685-90 11
114. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003;25:2754-64 11
115. Wong TY, Szeto CC, Chow KM, et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005;46:713-19 11
116. Chiang CK, Ho TI, Peng YS, et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 2007;30:3-7 11
117. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99 11
118. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58 11
119. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14 12
120. Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-44 12
121. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4 12
122. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62 12
123. He YL, Kulmatycki K, Zhang Y, et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther 2013; In press 12
124. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65 12
125. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008;57(Suppl 1):A160; 538-P 12
126. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9 12
127. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55 12
128. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54 12
129. Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab 2012;14:1032-9 13
130. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Exp Opin Drug Metab Toxicol 2011;7:1561-76 13
131. Cooper M VEM, Emser A, Patel S, Worle HJ. Efficacy and safety of linagliptin in patients with type 2 diabetes with or without renal impairment: results from a global Phase 3 program. Diabetes 2011;60:abstract 1068-P 13
132. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-44 13
133. Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76 13
134. Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012;8:383-94 13
135. Scheen AJ. Efficacy and safety of Jentadueto (linagliptin plus metformin). Expert Opin Drug Safety 2013;12(2):275-89 13
136. Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract 2010;90:182-90 13
137. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509 13
138. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011;58:979-87 13
139. Lukashevich V, Schweizer A, Foley JE, et al. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-8 14
140. Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32 14
141. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46 14
142. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76 14
143. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85 14
144. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312 14
145. Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:132-40 14
146. Kasichayanula S, Liu X, Benito MP, et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; published on line 2012/12/06; doi: 10.1111/bcp.12056 14
147. Weise WJ, Sivanandy MS, Block CA, et al. Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:e22-3 14
148. Lopez-Ruiz A, del Peso-Gilsanz C, Meoro-Aviles A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 2010;32:559-61 14
149. Kaakeh Y, Kanjee S, Boone K, et al. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012;32:e7-11 15
150. Pendergrass M, Fenton C, Haffner SM, et al. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012;14:596-600 15
151. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27 15
152. Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905 15
153. Davidson JA, Brett J, Falahati A, et al. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-55 15
154. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984;27:351-7 15
155. Runyan JW Jr, Hurwitz D, Robbins SL. Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes. N Engl J Med 1955;252:388-91 15
156. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70 15
157. Biesenbach G, Raml A, Schmekal B, et al. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003;20:642-5 15
158. Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med 2011;4:827-35 15
159. Rave K, Heise T, Pfutzner A, et al. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001;24:886-90 16
160. Czock D, Aisenpreis U, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 2003;41:492-7 16
161. Holmes G, Galitz L, Hu P, et al. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469-76 16
162. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012;35:1970-4 16
163. Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant 2006;21:553-4 16
164. McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs 2002;62:1357-64; discussion 65-6